J
Jeremy J. Pappacena
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 7
Citations - 82
Jeremy J. Pappacena is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Leukemia & Pentostatin. The author has an hindex of 3, co-authored 7 publications receiving 49 citations. Previous affiliations of Jeremy J. Pappacena include Allegheny Health Network.
Papers
More filters
Journal ArticleDOI
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
TL;DR: This small series suggests blinatumomab’s concurrent with commercially available TKIs as consolidative therapy to spare toxicities of conventional chemotherapy is a safe and effective consolidation strategy for patients with Ph’+ ALL to achieve or maintain CMR.
Journal ArticleDOI
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
TL;DR: The relevant drug–drug and drug–food interactions associated with ibrutinib, acalabrutinIB, and zanubrut inib are discussed and clinical practice recommendations for managing these interactions are provided based on the available literature.
Journal ArticleDOI
Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Ryan J. Daley,Sridevi Rajeeve,Charlene C. Kabel,Jeremy J. Pappacena,Sarah E. Stump,Jessica A. Lavery,Martin S. Tallman,Mark B. Geyer,Jae H. Park +8 more
TL;DR: This study suggests that while hepatotoxicity and other known adverse effects are common, with careful monitoring, pegaspargase can safely be administered to adults with ALL age ≥40 years old.
Journal ArticleDOI
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
TL;DR: HCL and HCLv are uncommon lymphoid neoplasms that lead to a characteristic constellation of symptoms, and the emergence of PAs and novel targeted agents have improved the likelihood and durability of responses for these patients.
Journal ArticleDOI
Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
TL;DR: The primary objectives were to characterize the safety/toxicity profile and rates of MRD negativity by flow cytometry (FACS) and/or quantitative real-time PCR for BCR-ABL1 transcripts following consolidation or re-induction w/ BLIN+TKI, and to deepen responses.